Scilex (NASDAQ:SCLX – Get Free Report) and Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.
Institutional and Insider Ownership
69.7% of Scilex shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Scilex and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scilex | -1,414.57% | N/A | -147.00% |
| Cumberland Pharmaceuticals | -34.40% | -28.81% | -9.25% |
Risk and Volatility
Scilex has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
Earnings and Valuation
This table compares Scilex and Cumberland Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scilex | $30.25 million | 0.45 | -$358.73 million | ($49.70) | -0.03 |
| Cumberland Pharmaceuticals | $44.52 million | 1.78 | -$2.84 million | ($0.71) | -7.46 |
Cumberland Pharmaceuticals has higher revenue and earnings than Scilex. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Scilex and Cumberland Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scilex | 1 | 0 | 0 | 0 | 1.00 |
| Cumberland Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Summary
Cumberland Pharmaceuticals beats Scilex on 7 of the 11 factors compared between the two stocks.
About Scilex
Scilex Holding Company (NASDAQ:SCLX) is a pharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. The company’s portfolio is intended to address conditions that may otherwise require opioid-based therapies, with an emphasis on prescription medicines and locally or systemically delivered treatments. Scilex’s commercial products include ZTlido, a prescription lidocaine topical system approved for the treatment of pain associated with postherpetic neuralgia; ELYXYB, an oral solution of celecoxib indicated for the acute treatment of migraine with or without aura in adults; and Gloperba, an oral liquid formulation of colchicine used to treat and prevent gout flares.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company headquartered in Nashville, Tennessee. The company develops, acquires and commercializes prescription medicines, with a focus on products that address unmet needs in critical care, gastroenterology, pain management and other specialty areas. Its portfolio has included Caldolor (ibuprofen injection), Acetadote (acetylcysteine injection), Kristalose (lactulose for oral solution), Vaprisol (conivaptan hydrochloride injection) and Omeclamox-Pak, a treatment for certain Helicobacter pylori infections.
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.
